Drug intelligence / Profile preview

NOBO-204

Development stage: Unknown
Lead developer: NOBO Medicine
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

**NOBO-204** is a NOBO Medicine oncology combination program comprising the covalent Bruton's tyrosine kinase inhibitor **poseltinib**, the cereblon E3-ligase-modulating agent **golcadomide**, and the anti-CD20 monoclonal antibody **rituximab**. The regimen is being developed for relapsed or refractory diffuse large B-cell lymphoma, combining inhibition of B-cell receptor signaling with cereblon-mediated immunomodulatory protein degradation and CD20-directed B-cell depletion.

Other names: poseltinib + golcadomide + rituximab

Targets

CRBN (Cereblon)BTK (Bruton tyrosine kinase)CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on NOBO-204.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NOBO-204.

Explore the full profile